ArQule Inc. (ARQL) and partner Daiichi Sankyo recently announced disappointing phase II results on oncology candidate, tivantinib (ARQ 197). The study evaluated ArQule’s lead pipeline candidate, tivantinib, in combination with Pfizer’s (PFE) Camptosar (irinotecan) and Bristol-Myers Squibbs/Eli Lilly’s (BMY/LLY) Erbiutx (cetuximab) in patients with refractory or relapsed colorectal cancer (CRC).
The study failed to meet its [...]
• Bio technology company ArQule Inc.’s (NASDAQ:ARQL) share prices gained 11.91% to close at $6.67 after the company's experimental treatment for liver cancer reported a positive outcome in its Phase II trial
• Share prices of discount carrier Sprint Airlines Inc. (NASDAQ:SAVE) declined 5.53% after the company announced plans to sell 11 million shares in a [...]
ArQule, Inc. (Nasdaq: ARQL) today announced a Special Protocol Assessment agreement with the U.S. Food and Drug Administration for the design of a Phase 3 trial of ARQ 197 in patients with non-small cell lung cancer of non-squamous histology.
Daiichi Sankyo Co., Ltd., the holder of the Investigational New Drug application for ARQ 197 and ArQule's partner for the development of the compound, will conduct the Phase 3 trial, which is planned for initiation later this year.
Good end to a good month
Today started out with ARQL and I traded it a few times today. I started out long at the open then went short where I made the bulk of the gains and then went short in small size a couple more times including near the end of the day. [...]
Subscribe to ArQule (ARQL) content from the Wikinvest Wire
